Credit Agreements in the Biotechnology Industry
395 Contracts & Agreements
- AbbVie Inc. (9 contracts)
- ACHIEVE LIFE SCIENCES, INC. (3)
- ADiTx Therapeutics, Inc. (9)
- ADMA BIOLOGICS, INC. (15)
- AKCEA THERAPEUTICS, INC. (1)
- Akebia Therapeutics, Inc. (2)
- Akero Therapeutics, Inc. (1)
- Alexion Pharmaceuticals (6)
- Alkermes plc. (3)
- Alliqua BioMedical, Inc. (5)
- ALNYLAM PHARMACEUTICALS, INC. (2)
- ALX ONCOLOGY HOLDINGS INC (2)
- Amgen Inc. (9)
- AMICUS THERAPEUTICS, INC. (2)
- AmpliPhi Biosciences Corp (6)
- Anika Therapeutics (3)
- Aptevo Therapeutics Inc. (6)
- ARCA biopharma, Inc. (1)
- Arcturus Therapeutics Holdings Inc. (2)
- Athenex, Inc. (10)
- ATOSSA GENETICS INC (2)
- Avid Bioservices, Inc. (2)
- Avita Therapeutics, Inc. (2)
- AZIYO BIOLOGICS, INC. (6)
- AzurRx BioPharma, Inc. (1)
- BIOCRYST PHARMACEUTICALS INC (2)
- Biogen Inc. (5)
- Biohaven Pharmaceutical Holding Co Ltd. (1)
- BIOMARIN PHARMACEUTICAL INC (2)
- BIOTIME INC (10)
- BioXcel Therapeutics, Inc. (4)
- C4 Therapeutics, Inc. (2)
- CANCER GENETICS, INC (14)
- CareDx, Inc. (4)
- CATABASIS PHARMACEUTICALS INC (1)
- Cellular Biomedicine Group, Inc. (4)
- Coherus BioSciences, Inc. (2)
- CURIS INC (6)
- Dermira, Inc. (1)
- Eagle Pharmaceuticals, Inc. (3)
- Emerald Bioscience, Inc. (5)
- Emergent BioSolutions Inc. (8)
- Epizyme, Inc. (1)
- EXICURE, INC. (4)
- Fibrocell Science, Inc. (1)
- Flexion Therapeutics Inc (5)
- Fortress Biotech, Inc. (6)
- GALECTIN THERAPEUTICS INC (4)
- Gilead Sciences (3)
- Gossamer Bio, Inc. (5)
- HALOZYME THERAPEUTICS INC (4)
- HARBOR DIVERSIFIED, INC. (7)
- HUMANIGEN, INC (2)
- iBio, Inc. (9)
- IMMUCELL CORP (1)
- IMPEL NEUROPHARMA INC (1)
- INFINITY PHARMACEUTICALS, INC. (1)
- Inmune Bio, Inc. (1)
- INOVIO PHARMACEUTICALS, INC. (1)
- INSMED Inc (1)
- Invitae Corp (4)
- IONIS PHARMACEUTICALS INC (1)
- IRONWOOD PHARMACEUTICALS INC (5)
- Kadmon Holdings, Inc. (8)
- Kura Oncology, Inc. (1)
- MANNKIND CORP (4)
- MEDICINOVA INC (1)
- MeiraGTx Holdings plc (2)
- MERRIMACK PHARMACEUTICALS INC (1)
- MiMedx Group, Inc. (4)
- Molecular Templates, Inc. (3)
- Myriad Genetics, Inc. (2)
- NANOVIRICIDES, INC. (1)
- Natera, Inc. (3)
- NEUROCRINE BIOSCIENCES INC (2)
- Nuo Therapeutics, Inc. (3)
- Opko Health, Inc. (13)
- ORAGENICS INC (3)
- Orgenesis Inc. (5)
- Oyster Point Pharma, Inc. (1)
- PDL BIOPHARMA, INC. (10)
- Pfenex Inc. (7)
- PORTOLA PHARMACEUTICALS INC (2)
- PROGENITY, INC. (6)
- PTC THERAPEUTICS, INC. (7)
- RECURSION PHARMACEUTICALS, INC. (1)
- Regeneron Pharmaceuticals (7)
- Retrophin, Inc. (6)
- Rezolute, Inc. (2)
- RIGEL PHARMACEUTICALS INC (3)
- Sarepta Therapeutics, Inc. (4)
- Seres Therapeutics, Inc. (1)
- Sorrento Therapeutics, Inc. (4)
- Spectrum Pharmaceuticals, Inc. (2)
- Stellar Biotechnologies, Inc. (1)
- Synthetic Biologics, Inc. (2)
- TG THERAPEUTICS, INC. (3)
- United Therapeutics Corp (5)
- VBI Vaccines Inc (6)
- VERACYTE, INC. (1)
- Verastem, Inc. (1)
- Vertex Pharmaceuticals Inc (3)
- WINDTREE THERAPEUTICS INC (2)
- Zai Lab Ltd (1)
- Fourth Amendment to Credit Agreement and Guaranty, dated March 20, 2024, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower,... (BioXcel Therapeutics, Inc., Filed With SEC on March 22, 2024)
- Warrant Agreement, by and between Akero Therapeutics, Inc. and Hercules Private Credit Fund 1 L.P., dated March 12, 2024 (Akero Therapeutics, Inc., Filed With SEC on March 18, 2024)
- Consent and Amendment to Amended and Restated Notes Purchase Agreement and Guaranty, dated December 20, 2023, by and among MeiraGTx Holdings plc, as issuer, the subsidiary... (MeiraGTx Holdings plc, Filed With SEC on March 15, 2024)
- Amendment No. 2 to Credit Agreement, dated as of March 12, 2024, by and among the Company, the lenders party thereto and Bank of America, N.A. as administrative Agent (Avid Bioservices, Inc., Filed With SEC on March 14, 2024)
- Amended Credit Agreement, dated as of October 3, 2022 and amended on September 6, 2023 and March 13, 2024, by and between the Company and Mattress Liquidators, Inc (AzurRx BioPharma, Inc., Filed With SEC on March 14, 2024)
- Second Amendment to Convertible Credit and Security Agreement (AmpliPhi Biosciences Corp, Filed With SEC on March 4, 2024)
- First Amendment to Credit and Security Agreement (AmpliPhi Biosciences Corp, Filed With SEC on March 4, 2024)
- Credit and Security Agreement, dated March 4, 2024 (AmpliPhi Biosciences Corp, Filed With SEC on March 4, 2024)
- Second Amendment to Third Amended and Restated Credit Agreement, among Eagle Pharmaceuticals, Inc., as borrower, JPMorgan Chase Bank, N.A., as administrative agent, and the... (Eagle Pharmaceuticals, Inc., Filed With SEC on March 1, 2024)
- Allonge to and Amendment of Line of Credit between the Company and Gorham Savings Bank, dated February 22, 2024 (IMMUCELL CORP, Filed With SEC on February 27, 2024)
- Waiver and First Amendment to Orbimed Credit Agreement (Avita Therapeutics, Inc., Filed With SEC on February 22, 2024)
- Line of Credit Agreement between the Company and Dr. Anil R. Diwan, dated November 13, 2023 (NANOVIRICIDES, INC., Filed With SEC on February 16, 2024)
- Third Amendment to Credit Agreement and Guaranty dated February 12, 2024, which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the... (BioXcel Therapeutics, Inc., Filed With SEC on February 12, 2024)
- Unofficial English Translation of Maximum Credit Contract, dated as of February (Zai Lab Ltd, Filed With SEC on February 8, 2024)
- Schedule to Credit and Security Agreement, dated January 16, 2024, by and between iBio, Inc. and Loeb Term Solutions LLC (iBio, Inc., Filed With SEC on January 19, 2024)
- Credit and Security Agreement, dated January 16, 2024, by and between iBio, Inc. and Loeb Term Solutions LLC (iBio, Inc., Filed With SEC on January 19, 2024)
- Limited Waiver and First Amendment to Third Amended and Restated Credit Agreement, among Eagle Pharmaceuticals, Inc., as borrower, JPMorgan Chase Bank, N.A., as administrative... (Eagle Pharmaceuticals, Inc., Filed With SEC on January 16, 2024)
- Eighth Amendment to Credit Agreement dated December 22, 2023 between iBio CDMO LLC and Woodforest National Bank (iBio, Inc., Filed With SEC on December 26, 2023)
- Amended and Restated Registration Rights Agreement, dated December 5, 2023, among the Company and Oaktree-TCDRS Strategic Credit, LLC, Oaktree-Forrest Multi-Strategy, LLC,... (BioXcel Therapeutics, Inc., Filed With SEC on December 6, 2023)
- Waiver and First Amendment to Credit Agreement and Guaranty, by and between the Company, the lenders party thereto and Oaktree Fund Administration LLC dated November 13, 2023 (BioXcel Therapeutics, Inc., Filed With SEC on November 14, 2023)
- Amendment No. 1 to the Sales Agreement with Cantor and Credit Suisse, dated August 25, 2023 (ALX ONCOLOGY HOLDINGS INC, Filed With SEC on November 13, 2023)
- Amendment No. 1 to Credit Agreement, dated as of October 27, 2023, among Avid Bioservices, Inc., as the Borrower, the Lenders party hereto, and Bank of America, N.A., as... (Avid Bioservices, Inc., Filed With SEC on November 2, 2023)
- Credit Agreement, effective as of October 20, 2023, by and between the Company and Pardeep Nijhawan Medicine Professional Corporation (Stellar Biotechnologies, Inc., Filed With SEC on October 23, 2023)
- Warrant Certificate, dated October 18, 2023, by and between the Company, and OrbiMed Royalty & Credit Opportunities IV, LP (Avita Therapeutics, Inc., Filed With SEC on October 18, 2023)
- Seventh Amendment to Credit Agreement dated October 4, 2023 between iBio CDMO LLC and Woodforest National Bank and Fifth Amendment to the Guaranty dated October 4, 2023 between... (iBio, Inc., Filed With SEC on October 10, 2023)
- Third Amendment to Credit Agreement dated October 2, 2023 (IMPEL NEUROPHARMA INC, Filed With SEC on October 4, 2023)
- Sixth Amendment, dated September 18, 2023, to the Credit Agreement by and between iBio CDMO LLC and Woodforest National Bank (iBio, Inc., Filed With SEC on September 21, 2023)
- Credit Agreement, dated as of August 28, 2023 among Biogen Inc., JPMorgan Chase Bank N.A., as administrative agent and the other lenders party thereto (Biogen Inc., Filed With SEC on September 1, 2023)
- Consent and Amendment to Amended and Restated Note Purchase Agreement and Guaranty, dated August 10, 2023, by and among MeiraGTx Holdings plc, as issuer, the subsidiary guarantors... (MeiraGTx Holdings plc, Filed With SEC on August 10, 2023)
- REVOLVING LINE OF CREDIT NOTE (Arcturus Therapeutics Holdings Inc., Filed With SEC on August 7, 2023)
- CREDIT AGREEMENT (Arcturus Therapeutics Holdings Inc., Filed With SEC on August 7, 2023)
- First Amendment to Secured Convertible Credit and Security Agreement (AmpliPhi Biosciences Corp, Filed With SEC on July 11, 2023)
- Credit and Security Agreement, dated July 10, 2023 (AmpliPhi Biosciences Corp, Filed With SEC on July 11, 2023)
- First Amendment, dated as of May 12, 2023, to the Credit Agreement, dated August 10, 2022, by and among Aziyo Biologics, Inc., SWK Funding LLC, as Agent and the Lenders from time... (AZIYO BIOLOGICS, INC., Filed With SEC on May 12, 2023)
- Amendment No. 2 to the Credit Agreement (HALOZYME THERAPEUTICS INC, Filed With SEC on May 9, 2023)
- Warrant Agreement, dated March 31, 2023, by and between TG Therapeutics, Inc. and Hercules Private Credit Fund 1 L.P (TG THERAPEUTICS, INC., Filed With SEC on May 8, 2023)
- Amended and Restated Warrant Agreement, dated March 31, 2023, by and between TG Therapeutics, Inc. and Hercules Private Credit Fund 1 L.P (TG THERAPEUTICS, INC., Filed With SEC on May 8, 2023)
- Amendment No. 2 to the Credit and Guaranty Agreement, dated as of May 1, 2023 (ADMA BIOLOGICS, INC., Filed With SEC on May 2, 2023)
- Credit Agreement and Guaranty, dated April 27, 2023, among Seres Therapeutics, Inc., a Delaware corporation, as the borrower, the subsidiary guarantors from time to time party... (Seres Therapeutics, Inc., Filed With SEC on April 27, 2023)
- Second Amended and Restated Revolving Credit Agreement, dated as of March 28, 2023, among AbbVie, the lenders and other parties party thereto and JPMorgan Chase Bank, N.A., as... (AbbVie Inc., Filed With SEC on March 28, 2023)